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Human illness routinely fails to fit neatly into the con-
structs we define as “diseases”. In fact, the very concept of
a “disease” as a discrete nameable entity is useful only
insofar as it informs our understanding of the pathophysi-
ologic phenomena affecting a patient, or provides clinical
information regarding prognosis and therapy. Nosology, the
study of disease classification, is intrinsically based on
Cartesian epistemologydmeaning that analytic approaches
can uncover fundamental truths about the natural universe,
including the naming of identifiable entities we are able to
observe and measure. However, this Cartesian conception
of nosologic certainty can fail to account for the fact that
biology is a spectrum. While some individuals’ illnesses are
dead center within any given construct, there are others
who must arbitrarily be labeled as having one or the other
disease based on our analytical constructs, not on the in-
dividuals’ behavior or properties. One has either sarcoidosis
OR hypersensitivity pneumonitisdnot both. One has either
idiopathic pulmonary fibrosis OR non-specific interstitial
pneumoniadnot both. And so on. Despite our practical
need to label, all of us routinely diagnose and treat in-
dividuals who fall somewhere in between our simple
constructs.
Judson et al. have dived into murky nosologic waters by
suggesting in this issue that some patients labeled with
sarcoidosis may in fact have granulomatous reactions caused
by connective tissue diseases (CTD) like scleroderma [1].
They reviewed carefully-vetted diagnoses from two aca-
demic medical centers, and found a statistically unexpected
surfeit of patients with co-existence of sarcoidosis and CTD.
Their findings may be due to referral bias, ascertainment
bias, suboptimal specificity of diagnostic criteria for CTD in
the setting of another immune-mediated inflammatory dis-
order (sarcoidosis) or overlapping pathophysiologic mecha-
nisms. An alternative explanation, one highlighted by the0954-6111/$ - see front matter ª 2013 Elsevier Ltd. All rights reserved
http://dx.doi.org/10.1016/j.rmed.2013.07.004authors, is that some of the patients’ granuloma syndromes
were actually a reaction to CTD rather than a manifestation
of “true” sarcoidosis. As they noted, their data cannot pro-
vide definitive answers among the competing explanations.
An existential question arises from observations like this
one: how important is it to have a “purist” definition of
sarcoidosis? Does splitting the construct of “sarcoidosis” into
parts improve our ability to prognosticate, treat, or study
our patients?
One way to handle the uncertain distinction between
immutable universal knowledge (truth) and useful con-
structs (empirical or practical forms of knowing) is to pass
on the question by focusing not on disease entities but on
syndromes. In sarcoidosis, this approach has been termed
the “sarcoidoses” [2]. Whether it is useful to be “lumpers”
or “splitters” of multisystem granuloma syndromes is being
debated right now, where the theories of sarcoidosis as a
single phenomenon with variable clinical phenotypes [3]
versus a spectrum of granulomatous inflammation (sar-
coidoses) [4] are competing nosologic hypotheses that will
be tested by science and time. Thus, a range of entities are
variably labeled as sarcoidosis, including granulomatous
disorders associated with World Trade Center dust [5],
medications (interferons or tumor necrosis antagonists)
[6,7], pediatric granulomatoses [8], necrotizing sarcoid
granulomatosis, and single organ granulomatous syndromes
affecting the skin, liver, eye or heart [9,10]. Clearly there
are some patients with these phenotypes who are better
approached as if they fit a purist definition of sarcoidosis,
and others who behave much differently. As a result, the
clinical approach to each might best be individualized to
focus on behavior and manifestations, rather than on a
label based on a construct [11].
In illnesses with unknown etiology and no single vali-
dated confirmatory test, diagnosis relies on meeting a
set of standards agreed to be definitional by implied
consensus or expert recommendations. There is no work-
ing group definition for a fractured humerus, but there is a
shared understanding of what that term implies. In more
complex diseases like sarcoidosis and CTD, a set of criteria
must be met to label an individual as having the diagnosis.
Even when there are criteria for defining the presence of a.
1286 Editorialbroader construct, such as a sarcoidosis syndrome or an
overlap CTD syndrome, the interpretation of the proposed
diagnostic criteria, the specific testing used to evaluate
them, when in the course of a pathophysiologic process
they are assessed, and how avidly alternatives are pur-
sued may all lead to substantial diagnostic variation when
they are operationalized. Such criterion variance has im-
plications for determining prevalence, studying natural
history, performing translational or clinical research, and
routine clinical care. One can consider the different re-
sults that might be obtained in two parallel studies: one
that requires histologic confirmation of sarcoidosis
involving at least one organ and evidence of a second
involved organ (purist definition) compared with a study
that applies looser definitions, such as a compatible
clinicoradiologic picture of isolated pulmonary, cardiac or
ocular “sarcoidosis”.
Until the pathophysiology of the disease we recognize as
sarcoidosis can be more fully elucidated, we will be forced
to define sarcoidosis phenomenologically. Analogous with
gene expression clustering techniques, classification of
multisystem granulomatous illness in the current era may
involve careful delineation of which syndromes behave
more similarly and which are more divergent. As such,
there will continue to be clinical and academic tension
between more specific (splitters) and more sensitive
(lumpers) criteria for sarcoidosis.
The presence of uncertainty does not eliminate the need
to follow careful principles when assigning a diagnosis of
sarcoidosis. We still must exclude known causes of granu-
lomatous reactions prior to arriving at a diagnosis [12]. A
reasonable heuristic for diagnosis is an empiric one, as
suggested by Dr. Judson: “the diagnosis of sarcoidosis. is
arbitrarily made when the statistical likelihood of alterna-
tive diagnoses becomes too small to warrant further
investigation” [13]. However, since the cause of sarcoidosis
is unknown, over-reliance on exclusion of all diseases
associated with granulomatous reactions, as well as overly
strict application of diagnostic criteria will necessarily
exclude many patients whose pathophysiology or clinical
care might be best aligned with that for more typical
sarcoidosis. So, while true that patients with contempora-
neous CTD and sarcoidosis might instead have variants of
either that look alike, the definition may be less important
than the individuals’ behavior, along with a healthy dose of
clinical skepticism.
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